BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range [Yahoo! Finance]
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range
A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Undervalued Narrative Gains Traction [Yahoo! Finance]
BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)